|会社名||Masimo Corp. （マシモ）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Electromedical_Electrotherapeutic Apparatus|
|業種||医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care）|
|概要||事業概要 マシモ(Masimo Corporation) は医療技術企業であり、非侵襲患者モニタリング製品を開発・製造・販売する。同社の事業はマシモ信号抽出技術（SET）パルスオキシメトリーと知られる測定スルーモーションおよび低灌流パルスオキシメトリーモニタリングである。製品には光学特性、光学臓器酸素濃度測定、電気、脳機能モニタリング、音響呼吸モニタリング、呼気モニタリングなどの血液成分の非侵襲的モニタリングが含まれる。同社はまたRoot患者のモニタリングおよび接続プラットフォーム、Radical-7ベッドサイドとポータブル患者モニタ、Radius-7ウェアラブル無線患者モニタを開発する。同社はPatient SafetyNetリモート患者監視監視システムを提供する。これにより、患者はパーソナルコンピュータベースのモニタまたはポケベル、ボイスオーバーインターネットプロトコル（IP）電話、スマートフォンを通じてケア提供者によって監視される。 マシモは、米国の医療技術企業。非侵襲的患者監視製品を開発、製造、売買に従事する。患者監視ソリュ―ションは、一般的にはモニタ―や回路基板とセンサ―に組み込まれる。主にに直接パ―トナ―代理店もしくは元の機器メ―カ―を通じて、病院、救急医療サ―ビス・プロバイダ―、医師、獣医師、介護施設や消費者に同社製品を販売する。 Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo's mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.4 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,5 improve CCHD screening in newborns,6 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.7-10 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,11 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.12 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient's physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo's family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™.|
|本社所在地||52 Discovery Irvine CA 92618 USA|
|代表者氏名||Joseph E. Kiani ジョセフ・E・キアニ|
|代表者役職名||Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Masimo Corporation revenues increased 9% to $424.6M. Net income decreased 7% to $89.5M. Revenues reflect United States segment increase of 10% to $281.2M Europe Middle East and Africa segment increase of 22% to $78.4M. Net income was offset by Selling general and administrative increase of 7% to $142.6M (expense) Research and development increase of 23% to $37.7M (expense).|
mHealth Market Raises US$ 246,820.4 Million to Acquire and Grow with LifeWatch, Medtronic, Masimo, Cisco Systems, athenahealth 2021/08/04 13:26:04 OpenPR
The Insight Partners market research study titled '' mHealth Market to 2025 - Global Analysis and Forecasts by Product, Procedure.The report highlights the trends prevalent in the global mHealth Market and the factors driving the market along with the restraints
Does Earnings Surprise History Hold Any Clue for NASDAQ:MASI, NASDAQ:SLAB, NYSE:ESS, NYSE:TWI 2021/08/01 14:58:00 Stock Market Daily
Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post Does Earnings Surprise History Hold Any Clue for NASDAQ:MASI, NASDAQ:SLAB, NYSE:ESS, NYSE:TWI appeared first on .
Carbon Dioxide Monitors Market Comprehensive Study Explore Huge Growth In Future : Criticare , GE Healthcare, Invivo, Masimo 2021/07/30 14:30:32 OpenPR
Carbon Dioxide (CO2) Monitors Market report gives a thorough analysis of this dynamic focus of this market with a secondary search. The report sheds light on the Carbon Dioxide (CO2) Monitors forecast, share, demand, development patterns, and also their current
Landsberg, Bennett, & Dubbaneh LLC Buys Zoetis Inc, Establishment Labs Holdings Inc, The ... 2021/07/29 22:38:07 GuruFocus
Related Stocks: ESTA , MDT , TREX , SITE , DIA , ORA , ZTS , XLE , XLB , XLF , XLI , ROAD , MRCY , TDOC , MASI , IWF , BMY , EBS ,
Medical Temperature Monitoring Devices Market Size 2021, Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2027 | Mediim LTD, Masimo, 3M Company 2021/07/29 08:03:32 OpenPR
The global Medical Temperature Monitoring Devices Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research
Latest Research Report On Hemoglobin Monitor Market 2021. Major Players Included Masimo, Bayer, Siemens, Hill-Rom Holdings, Philips, etc. 2021/07/13 09:11:19 Tramways Monthly
The Latest Hemoglobin Monitor Market Research Report is a comprehensive and in-depth analysis of the global market published by Industry Growth Insights (IGI). It provides detailed information about the market, including current trends, drivers and challenges. This report will help companies take a correct business decision and gain competitive advantage in the market. The report 
Global Patient Monitoring Devices Market Set to Hit New Highs: Expected to Reach USD 68.4 billion by 2027 2021/07/08 11:59:00 Intrado Digital Media
The leading players in the global patient monitoring devices market are Medtronic plc, Abbott Laboratories, Dragerwerk AG & Co. KGaA, Edwards Lifesciences Corporation, GE Healthcare, OMRON Corporation, Masimo Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Nihon Kohden Corporation, Natus Medical, Koninklijke Philips N.V., Getinge AB, Boston Scientific Corporation, Dexcom, Inc., Nonin Medical, Inc., Biotronik, Bio Telemetry, Inc., Schiller AG, F. Hoffmann-La Roche Ltd., Hill- Rom Holdings, Inc., and other prominent players. The leading players in the global patient monitoring devices market are Medtronic plc, Abbott Laboratories, Dragerwerk AG & Co. KGaA, Edwards Lifesciences Corporation, GE Healthcare, OMRON Corporation, Masimo Corporation, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Nihon Kohden Corporation, Natus Medical, Koninklijke Philips N.V., Getinge AB, Boston Scientific Corporation, Dexcom, Inc., Nonin Medical, Inc., Biotronik, Bio Telemetry, Inc., Schiller AG, F.
Worldwide Newborn Screening Industry to 2031 - Featuring ZenTech, Baebies and Masimo Among Others 2021/07/06 17:00:00 PR Newswire
DUBLIN, July 6, 2021 /PRNewswire/ -- The "Newborn Screening Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com''s offering. The report on the global newborn screening market studies the past as well as
New Study Evaluates the Ability of Masimo SedLine Brain Function Monitoring to Predict Neurological Outcomes and Long-term Survival in Post-Cardiac Arrest ICU Patients 2021/07/06 06:00:00 Wallstreet:Online
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Journal of Critical Care in which Dr. Tae Youn Kim and colleagues at the Dongguk University College of Medicine and Yonsei University College of Medicine in Korea evaluated the ability of two parameters provided by Masimo SedLine brain function monitoring to predict neurological outcomes and long-term survival in post-cardiac
Masimo accuses Apple of patent infringement 2021/07/01 20:13:27 Techtelegraph
Medical device company Masimo has accused Apple of patent infringement, filing a complaint against the company with the U.S. International Trade Commission yesterday. Bloomberg, which first spotted the news, reports that the accusations are specifically against Apples Series 6 smartwatch blood oxygenation tool, which uses light transmitted throughout the body to gauge blood oxygen levels. In  The post Masimo accuses Apple of patent infringement appeared first on TECHTELEGRAPH .
Masimo seeks Series 6 import ban in smartwatch fight with Apple 2021/06/30 21:10:54 Cult of Mac
Healthcare technology company Masimo Corp. has upped the ante in its legal fight with Apple. In a patent-infringement complaint filed today at the U.S. International Trade Commission in Washington, D.C., it said U.S. imports of the Apple Watch Series 6 should be halted. Masimo alleged that Apples smartwatch infringes five patents for devices that measure  (via Cult of Mac - Tech and culture through an Apple lens )
Masimo demands ITC ban Apple Watch Series 6 sales in America 2021/06/30 20:08:00 GlassWave
Masimo has filed a patent-infringement complaint at the U.S. ITC that seeks to ban imports of the Apple Watch Series 6 . . . The post Masimo demands ITC ban Apple Watch Series 6 sales in America appeared first on MacDailyNews.
Masimo requests Apple Watch import ban, alleging patent infringement 2021/06/30 18:49:47 Seeking Alpha
Medical device company Masimo wants Apple Watch Series 6 sales banned 2021/06/30 17:36:00 GlassWave
Masimo is expanding its legal battle against Apple. The medial device company has filed a patent infringement complaint agains the tech giant and is asking for a ban on impacts of the Apple Watch, reports Bloomberg. The post Medical device company Masimo wants Apple Watch Series 6 sales banned appeared first on Apple World Today.
Apple Watch Series 6 ban sought by medical device manufacturer Masimo 2021/06/30 16:27:00 GlassWave
Medical technology company Masimo is escalating its legal battle with Apple, filing a complaint that seeks an import ban on Apple Watch models. Credit: Andrew O''Hara, AppleInsider Masimo, which sued Apple in 2020 for alleged patent infringement and theft of trade secrets, filed a complaint with the U.S. International Trade Commission on Tuesday. The filing claims that the Apple Watch Series 6 infringes on five patents focused on technology that uses light to measure blood oxygen levels.Read more